Opinion 13.7: Cosmos And Culture Let's Look Beyond Random Trials When Assessing New Drug Treatments November 19, 2012 • Commentator Stuart Kauffman outlines the findings of a paper he co-authored in the journal PLOS ONE that questions the FDA's total commitment to "randomized controlled trials" for drug testing when he says an alternative called "Team Learning" may be more effective in some cases.
